Trading Signals: SGEN Stock Price Prediction and Forecast (Fri. May. 30, 2003 - Wed. Dec. 13, 2023)(Seattle Genetics, Inc.)
| SGEN latest price $50.9400 (-2.67%) ($49.9000 - $52.4400) on Mon. Apr. 2, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.59% (three month average) | RSI | 27 | Latest Price | $50.9400(-2.67%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | SGEN declines -5.6% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support SGEN advance at 0% a week (0% probability) IBB(32%) VFMO(29%) XLV(29%) BOTZ(27%) IVW(27%) | Factors Impacting SGEN price | SGEN will decline at least -1.295% in a week (0% probabilities). VIXM(-10%) UUP(-8%) DIA(-4%) TLT(-3%) GDXJ(-3%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.295% (StdDev 2.59%) | Hourly BBV | 0 () | Intraday Trend | -1.7% | | | |
|
1 - 5 Day Possible Target | $42.93(-15.72%) | Resistance Level | $54.92 | 5 Day Moving Average | $51.95(-1.94%) | 10 Day Moving Average | $52.78(-3.49%) | 20 Day Moving Average | $54.92(-7.25%) | To recent high | -14.1% | To recent low | 1.6% | Market Cap | $8.857b | | | | Seattle Genetics, Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. |